FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1312-1314

  Costa de Oliveira, Sofia ^a   Miranda, Isabel Marcos ^a   Silva, Raquel M ^b   E Silva, Ana Pinto ^a   Rocha, Rita ^a   Amorim, António ^b   Rodrigues, Acácio Gonçalves ^a,c   Pina Vaz, Cidália ^a,c  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BACTERIAL DNA; CASPOFUNGIN; MEROPENEM; MICAFUNGIN; NORADRENALIN; PHENYLALANINE; PIPERACILLIN; PROLINE; SERINE; TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACUTE PANCREATITIS; AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD; CANDIDA ALBICANS; CANDIDA GLABRATA; CASE REPORT; CATHETER INFECTION; CENTRAL VENOUS CATHETER; FEMALE; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE DELETION; HUMAN; INVASIVE CANDIDIASIS; LAPAROSCOPIC SURGERY; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PERITONEAL FLUID; PHARMACOGENETICS; POINT MUTATION; PRIORITY JOURNAL;

AGED; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; MUTATION;

EID: 79952357849     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00589-10     Document Type: Article

References (26)

1. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
2. Bautista-Muñoz, C., X. M. Boldo, L. Villa-Tanaca, and C. Hernández-Rodríguez. 2003. Identification of Candida spp. by randomly amplified polymorphic DNA analysis and differentiation between Candida albicans and Candida dubliniensis by direct PCR methods. J. Clin. Microbiol. 41:414-420.
3. Castanheira, M., et al. 2010. Low prevalence of fks1 Hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 54:2655-2659.
4. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. M27-S3. CLSI, Wayne, PA.
6. Costa-de-Oliveira, S., C. Pina-Vaz, D. Mendonça, and A. Gonçalves Rodrigues. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 27:365-374.
7. Cota, J. M., et al. 2008. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob. Agents Chemother. 52:1144-1146. (Pubitemid 351358401)
8. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
9. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
10. Garcia-Effron, G., et al. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
11. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
12. Hernandez, S., et al. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383. (Pubitemid 38405501)
13. Kartsonis, N., et al. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. 49:3616-3623.
14. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
15. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
16. Laverdière, M., et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
17. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
18. Park, S., et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273. (Pubitemid 41060570)
19. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
20. Pfaller, M. A., and D. J. Diekema. 2002. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40:3551-3557.
21. Pfaller, M. A., et al. 2005. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49:4795-4797.
22. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
23. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
24. Thompson, G. R., III, et al. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
25. Walker, L. A., et al. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040.
26. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs 12:1313-1333.